Cargando…
MON-LB032 Real World Evidence Data on the Role of Sodium/Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonist in Chronic Kidney Disease Stage 3 Patients beyond Glycemic Control, at Glycemia Clinic- Kuwait
Introduction Diabetes remain the most common reason for progression to end stage renal disease. Chronic kidney disease (CKD) is a strong prediction of mortality in patients with diabetes.(1) Up to 40% of type two diabetes (T2D) will eventually suffer from kidney failure.(2) Sodium/glucose Cotranspor...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Endocrine Society
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550959/ http://dx.doi.org/10.1210/js.2019-MON-LB032 |